Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualized relapse rate (ARR) vs active comparator Ocrevus OPERETTA 2 Phase III […]

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Finance & Markets

More from Wednesday 21 October →